Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacy R Lindborg

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|October 13, 2005
Multiple imputation techniques in small sample clinical trialsSunni A Barnes, Stacy R Lindborg, John W Seaman
Psychopharmacology|June 27, 2003
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidolScot E Purdon, Neil Woodward, Stacy R Lindborg, et al.
Psychiatry Research|July 16, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patientsStacy R Lindborg, Charles M Beasley, Karla Alaka, et al.
The American Journal of Emergency Medicine|June 18, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patientsJohn Battaglia, Stacy R Lindborg, Karla Alaka, et al.
Pharmaceutical Statistics|September 14, 2007
The impact of missing data and how it is handled on the rate of false-positive results in drug developmentSunni A Barnes, Craig H Mallinckrodt, Stacy R Lindborg, et al.
Nature Reviews. Drug Discovery|August 2, 2014
Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivityStacy R Lindborg, Charles C Persinger, Andreas Sashegyi, et al.
Clinical Therapeutics|July 18, 2003
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapyPadraig Wright, Karena Meehan, Martin Birkett, et al.
Expert Opinion on Investigational Drugs|February 26, 2026
Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findingsPremal H Thaker, Stacy R Lindborg, Ana Limon, et al.
Nature Reviews. Drug Discovery|February 20, 2010
How to improve R&D productivity: the pharmaceutical industry's grand challengeSteven M Paul, Daniel S Mytelka, Christopher T Dunwiddie, et al.
Vaccine|February 21, 2026
Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 studyKhursheed Anwer, Lauren Musso, Ninaad Lasrado, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|October 13, 2005
Multiple imputation techniques in small sample clinical trialsSunni A Barnes, Stacy R Lindborg, John W Seaman
Psychopharmacology|June 27, 2003
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidolScot E Purdon, Neil Woodward, Stacy R Lindborg, et al.
Psychiatry Research|July 16, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patientsStacy R Lindborg, Charles M Beasley, Karla Alaka, et al.
The American Journal of Emergency Medicine|June 18, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patientsJohn Battaglia, Stacy R Lindborg, Karla Alaka, et al.
Pharmaceutical Statistics|September 14, 2007
The impact of missing data and how it is handled on the rate of false-positive results in drug developmentSunni A Barnes, Craig H Mallinckrodt, Stacy R Lindborg, et al.
Nature Reviews. Drug Discovery|August 2, 2014
Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivityStacy R Lindborg, Charles C Persinger, Andreas Sashegyi, et al.
Clinical Therapeutics|July 18, 2003
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapyPadraig Wright, Karena Meehan, Martin Birkett, et al.
Expert Opinion on Investigational Drugs|February 26, 2026
Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findingsPremal H Thaker, Stacy R Lindborg, Ana Limon, et al.
Nature Reviews. Drug Discovery|February 20, 2010
How to improve R&D productivity: the pharmaceutical industry's grand challengeSteven M Paul, Daniel S Mytelka, Christopher T Dunwiddie, et al.
Vaccine|February 21, 2026
Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 studyKhursheed Anwer, Lauren Musso, Ninaad Lasrado, et al.
Pageof 2